WO2005037860A3 - Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv - Google Patents

Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv Download PDF

Info

Publication number
WO2005037860A3
WO2005037860A3 PCT/US2004/033238 US2004033238W WO2005037860A3 WO 2005037860 A3 WO2005037860 A3 WO 2005037860A3 US 2004033238 W US2004033238 W US 2004033238W WO 2005037860 A3 WO2005037860 A3 WO 2005037860A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
inhibitors
ns4a protease
serine proteases
relates
Prior art date
Application number
PCT/US2004/033238
Other languages
English (en)
Other versions
WO2005037860A2 (fr
Inventor
Kevin M Cottrell
Robert B Perni
Janos Pitlik
Original Assignee
Vertex Pharmaceuticals Incopor
Kevin M Cottrell
Robert B Perni
Janos Pitlik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020117029638A priority Critical patent/KR20120010278A/ko
Priority to NZ546663A priority patent/NZ546663A/en
Priority to JP2006534377A priority patent/JP2007532474A/ja
Priority to MXPA06004006A priority patent/MXPA06004006A/es
Priority to CN200480034568XA priority patent/CN1906208B/zh
Priority to EP04794554.8A priority patent/EP1692157B1/fr
Application filed by Vertex Pharmaceuticals Incopor, Kevin M Cottrell, Robert B Perni, Janos Pitlik filed Critical Vertex Pharmaceuticals Incopor
Priority to AU2004282148A priority patent/AU2004282148A1/en
Priority to CA002541634A priority patent/CA2541634A1/fr
Publication of WO2005037860A2 publication Critical patent/WO2005037860A2/fr
Publication of WO2005037860A3 publication Critical patent/WO2005037860A3/fr
Priority to IL174863A priority patent/IL174863A0/en
Priority to NO20062101A priority patent/NO20062101L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne des composés de formule (I) ou un de ses sels ou de ses mélanges pharmaceutiquement acceptables inhibant l'activité de la sérine protéase, en particulier l'activité de la NS3-NS4A protéase du virus de l'hépatite C. Les composés agissent par interférence avec le cycle de vie du virus de l'hépatite C et sont également utilisés en tant qu'agents antiviraux. L'invention concerne, de plus, des compositions comprenant lesdits composés utilisées ex vivo ou administrées à un patient souffrant d'une infection au HCV, ainsi que des procédés pour préparer lesdits composés. L'invention se rapporte également à des méthodes de traitement d'une infection au HCV chez un patient comprenant l'administration d'une composition comprenant un composé de l'invention. L'invention concerne, en outre, des procédés pour préparer lesdits composés.
PCT/US2004/033238 2003-10-10 2004-10-08 Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv WO2005037860A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NZ546663A NZ546663A (en) 2003-10-10 2004-10-08 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2006534377A JP2007532474A (ja) 2003-10-10 2004-10-08 セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
MXPA06004006A MXPA06004006A (es) 2003-10-10 2004-10-08 Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c.
CN200480034568XA CN1906208B (zh) 2003-10-10 2004-10-08 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
EP04794554.8A EP1692157B1 (fr) 2003-10-10 2004-10-08 Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv
KR1020117029638A KR20120010278A (ko) 2003-10-10 2004-10-08 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의 억제제
AU2004282148A AU2004282148A1 (en) 2003-10-10 2004-10-08 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA002541634A CA2541634A1 (fr) 2003-10-10 2004-10-08 Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv
IL174863A IL174863A0 (en) 2003-10-10 2006-04-09 Compounds that inhibit serine proteases and pharmaceutical compositions containing the same
NO20062101A NO20062101L (no) 2003-10-10 2006-05-10 Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51015603P 2003-10-10 2003-10-10
US60/510,156 2003-10-10
US51376803P 2003-10-23 2003-10-23
US60/513,768 2003-10-23

Publications (2)

Publication Number Publication Date
WO2005037860A2 WO2005037860A2 (fr) 2005-04-28
WO2005037860A3 true WO2005037860A3 (fr) 2005-11-10

Family

ID=34467967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033238 WO2005037860A2 (fr) 2003-10-10 2004-10-08 Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv

Country Status (14)

Country Link
US (2) US7208600B2 (fr)
EP (2) EP1692157B1 (fr)
JP (2) JP2007532474A (fr)
KR (2) KR20120010278A (fr)
CN (1) CN101857631A (fr)
AU (1) AU2004282148A1 (fr)
CA (1) CA2541634A1 (fr)
IL (1) IL174863A0 (fr)
MX (1) MXPA06004006A (fr)
NO (1) NO20062101L (fr)
NZ (1) NZ546663A (fr)
RU (1) RU2006115558A (fr)
TW (1) TW200528472A (fr)
WO (1) WO2005037860A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979327B (en) * 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
WO2001074768A2 (fr) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1613620A1 (fr) * 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
AU2004257288A1 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
JP4685775B2 (ja) 2003-09-18 2011-05-18 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
KR20120010278A (ko) * 2003-10-10 2012-02-02 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의 억제제
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
PT1677827E (pt) * 2003-10-27 2009-03-13 Vertex Pharma Associações para o tratamento do vhc
CA2554999A1 (fr) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
RU2441020C2 (ru) * 2005-08-02 2012-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы серинпротеазы
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
DK1999129T3 (da) 2005-10-11 2011-02-07 Intermune Inc Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007098270A2 (fr) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-cristaux et compositions pharmaceutiques les comprenant
CA2646229A1 (fr) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Inhibiteurs de protease de l'hepatite c deuteres
MX2008013119A (es) * 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (fr) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010518099A (ja) 2007-02-09 2010-05-27 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
PT2114924E (pt) 2007-02-27 2012-04-03 Vertex Pharma Co-cristais e composições farmacêuticas que compreendem os mesmos
EP2134717A2 (fr) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibiteurs de sérine protéases
CL2008001274A1 (es) * 2007-05-03 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
BRPI0811447A2 (pt) 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
MX2010002407A (es) 2007-08-30 2010-03-26 Vertex Pharma Cocristales y composiciones farmaceuticas que los comprenden.
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
CN101951770B (zh) 2007-12-21 2014-12-31 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
KR20150113217A (ko) 2007-12-21 2015-10-07 셀진 아빌로믹스 리서치, 인코포레이티드 Ｈｃｖ 프로테아제 억제제 및 이의 용도
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
MX2010008108A (es) * 2008-01-24 2010-09-22 Enanta Pharm Inc Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.
KR20100118991A (ko) 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
US8048862B2 (en) * 2008-04-15 2011-11-01 Intermune, Inc. Macrocyclic inhibitors of hepatitis C virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010045266A1 (fr) * 2008-10-15 2010-04-22 Intermune, Inc. Peptides antiviraux therapeutiques
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8073632B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101967A2 (fr) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Inhibiteurs de phosphothiophène et phosphothiazole vhc polymérase
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
WO2011038293A1 (fr) * 2009-09-28 2011-03-31 Intermune, Inc. Inhibiteurs peptiques cycliques de la réplication du virus de l'hépatite c
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
EP2513113B1 (fr) 2009-12-18 2018-08-01 Idenix Pharmaceuticals LLC Inhibiteurs du virus de l'hépatite c à base de 5,5-arylène ou hétéroarylène condensé
CA2795054A1 (fr) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Composes et compositions pharmaceutiques pour le traitement d'infections virales
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (fr) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Composés et compositions pharmaceutiques pour le traitement d'infections virales
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
WO2013039855A1 (fr) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Composés et compositions pharmaceutiques pour le traitement d'infections virales
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
CA2873315A1 (fr) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. Composes d'acide d-amine contre les maladies hepatiques
WO2013177188A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
WO2013177195A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EP2909223B1 (fr) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Composés dinucléotides contre une infection par le vhc
WO2014066239A1 (fr) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. Nucléosides 2', 4'-pontés pour l'infection par le vhc
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2938624A1 (fr) 2012-11-14 2015-11-04 IDENIX Pharmaceuticals, Inc. Ester de d-alanine d'analogue de sp-nucléoside
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137926A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2981542B1 (fr) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoronucléosides pour le traitement du vhc
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (fr) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. Pronucléotides phosphoramidates avec acides aminés d de composés halogéno pyrimidines pour le traitement des hépatopathies
WO2015042375A1 (fr) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2015061683A1 (fr) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (fr) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
EP3083654A1 (fr) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC Nucléosides 4'-or pour le traitement du vhc
EP2899207A1 (fr) 2014-01-28 2015-07-29 Amikana.Biologics Nouveau procédé pour tester l'inhibition de la protéase du HCV
WO2015134780A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Formes solides de promédicaments de 2'-chloro-2'-méthyl uridine pour lutter contre le vhc
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3131914B1 (fr) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
KR102568859B1 (ko) 2015-02-13 2023-08-21 옥스포드 드러그 디자인 리미티드 아미노아실-tRNA 합성효소 저해제로서 신규한 N-아실-아릴술폰아미드 유도체
KR20180114910A (ko) 2016-02-05 2018-10-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
EP3891508A1 (fr) 2018-12-04 2021-10-13 Bristol-Myers Squibb Company Procédés d'analyse utilisant une courbe d'étalonnage dans un échantillon par surveillance de réaction d'isotopologues multiples

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675112A1 (fr) * 1994-03-31 1995-10-04 Bristol-Myers Squibb Company Inhibiteurs de farnésyl-protéine-transférase contenant l'imidazole
WO1998017679A1 (fr) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c
WO2002008244A2 (fr) * 2000-07-21 2002-01-31 Schering Corporation Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c
WO2003006490A1 (fr) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Inhibiteurs bicycliques pontes de la serine protease
WO2003035060A1 (fr) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
WO2003087092A2 (fr) * 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c
WO2004092161A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
WO2004092162A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674513B1 (fr) 1992-12-29 1996-09-25 Abbott Laboratories Composes inhibant des proteases retrovirales
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CN1116288C (zh) 1996-04-23 2003-07-30 沃泰克斯药物股份有限公司 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
CA2254122A1 (fr) 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PT966465E (pt) 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
ATE283865T1 (de) 1997-08-11 2004-12-15 Boehringer Ingelheim Ca Ltd Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
JP4354632B2 (ja) 1997-08-11 2009-10-28 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎抑制剤ペプチド
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
JP4690545B2 (ja) 1998-03-31 2011-06-01 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
KR100652535B1 (ko) 1999-03-19 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 Ｉｍｐｄｈ 효소의 억제제
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
WO2001007407A1 (fr) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Inhibiteurs lactame de la protease ns3 du virus de l'hepatite c
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
CA2396504A1 (fr) 2000-02-29 2001-09-07 Dupont Pharmaceuticals Company Inhibiteurs de la protease ns3 du virus de l'hepatite c
WO2001074768A2 (fr) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
ES2317900T3 (es) 2000-04-05 2009-05-01 Schering Corporation Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2.
NZ521456A (en) 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AU8063701A (en) 2000-07-21 2002-02-05 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
CA2369970A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
JP2007524576A (ja) 2003-02-07 2007-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状のｃ型肝炎セリンプロテアーゼ阻害剤
DE10315645B4 (de) 2003-04-04 2005-07-14 Zf Boge Elastmetall Gmbh Hydraulisch dämpfendes Gummibuchsenlager für vertikale Montage
BRPI0409593A (pt) 2003-05-01 2006-05-02 Procter & Gamble composições lìquidas listradas para higiene pessoal contendo uma fase de limpeza e uma fase de benefìcio separada, compreendendo uma emulsão de água em óleo
ES2297424T3 (es) * 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
AU2004257288A1 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
JP4685775B2 (ja) 2003-09-18 2011-05-18 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
KR20120010278A (ko) * 2003-10-10 2012-02-02 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의 억제제
CA2554999A1 (fr) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675112A1 (fr) * 1994-03-31 1995-10-04 Bristol-Myers Squibb Company Inhibiteurs de farnésyl-protéine-transférase contenant l'imidazole
WO1998017679A1 (fr) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c
WO2002008244A2 (fr) * 2000-07-21 2002-01-31 Schering Corporation Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c
WO2003006490A1 (fr) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Inhibiteurs bicycliques pontes de la serine protease
WO2003035060A1 (fr) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
WO2003087092A2 (fr) * 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c
WO2004092161A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
WO2004092162A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JOHANSSON ANJA ET AL: "Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase): A comparative study of different C-terminals", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 11, no. 12, 12 June 2003 (2003-06-12), pages 2551 - 2568, XP002272318, ISSN: 0968-0896 *
PERNI R B ET AL: "Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 6, 2004, pages 1441 - 1446, XP002296491, ISSN: 0960-894X *
PERNI R B ET AL: "INHIBITORS OF HEPATITIS C VIRUS NS3.4A PROTEASE. PART 3: P2 PROLINE VARIANTS", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 8, 19 April 2004 (2004-04-19), pages 1939 - 1942, XP008037248, ISSN: 0960-894X *
PERNI ROBERT B ET AL: "Inhibitors of hepatitis C virus NS3cntdot4A protease 1. Non-charged tetrapeptide variants.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 22, 17 November 2003 (2003-11-17), pages 4059 - 4063, XP002317469, ISSN: 0960-894X *
POLIAKOV A ET AL: "Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors", BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1672, no. 1, 7 April 2004 (2004-04-07), pages 51 - 59, XP004501064, ISSN: 0304-4165 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Also Published As

Publication number Publication date
KR20060130027A (ko) 2006-12-18
AU2004282148A1 (en) 2005-04-28
JP2007532474A (ja) 2007-11-15
JP2011246487A (ja) 2011-12-08
US8039623B2 (en) 2011-10-18
MXPA06004006A (es) 2006-06-28
CA2541634A1 (fr) 2005-04-28
US7208600B2 (en) 2007-04-24
TW200528472A (en) 2005-09-01
EP2361925A1 (fr) 2011-08-31
IL174863A0 (en) 2008-02-09
EP1692157B1 (fr) 2013-04-17
WO2005037860A2 (fr) 2005-04-28
EP1692157A2 (fr) 2006-08-23
KR20120010278A (ko) 2012-02-02
US20050137140A1 (en) 2005-06-23
RU2006115558A (ru) 2007-11-20
US20070161789A1 (en) 2007-07-12
CN101857631A (zh) 2010-10-13
NZ546663A (en) 2010-01-29
NO20062101L (no) 2006-07-05

Similar Documents

Publication Publication Date Title
WO2005037860A3 (fr) Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv
WO2005077969A3 (fr) Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
WO2005007681A3 (fr) Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
WO2003087092A3 (fr) Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c
WO2005035525A3 (fr) Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
HK1065322A1 (en) Bridged bicyclic serine protease inhibitors
WO2004093798A3 (fr) Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c
WO2006039488A3 (fr) Inhibition de la protease ns3-ns4a du vhc
WO2004113365A3 (fr) Inhibiteurs de la tripeptide hepatite c serine protease
EP1441720B8 (fr) Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
WO2008106058A3 (fr) Inhibiteurs de sérine protéases
WO2004072243A3 (fr) Inhibiteurs macrocycliques de la serine protease de l'hepatite c
WO2008002924A3 (fr) Inhibiteurs macrocycliques quinoxalinyliques des protéases à sérine du virus de l'hépatite c
WO2009053828A3 (fr) Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c
WO2009076173A3 (fr) Composés à base de tripeptides fluorés inhibant la sérine protéase du vhc
WO2007143694A3 (fr) Inhibiteurs oximyles macrocycliques de la protéase de l'hépatite c

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480034568.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2541634

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 174863

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004006

Country of ref document: MX

Ref document number: 2006534377

Country of ref document: JP

Ref document number: 1020067006901

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004794554

Country of ref document: EP

Ref document number: 2006/02937

Country of ref document: ZA

Ref document number: 200602937

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 908/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 546663

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004282148

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006115558

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004282148

Country of ref document: AU

Date of ref document: 20041008

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004282148

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004794554

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067006901

Country of ref document: KR